Key information

🔎 Fund Overview

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. It focuses in treating fibrosis by inhibiting integrin-mediated activation of transforming growth factor beta (TGF-B). Its lead product candidate, bexotegrast (PLN-74809), is an oral small-molecule, dual-selective inhibitor of avß6 and avB1. Its second product candidate, PLN-1474, is a small-molecule, selective inhibitor of avB1 for treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition to its clinical programs, it is developing additional preclinical integrin-based programs targeting muscular dystrophies. It is also developing PLN-101095 an oral, dual inhibitor of αvß8 and αvß1 integrins for the treatment of solid tumors. Its clinical programs also include PLN-101325, an allosteric agonistic monoclonal antibody against α7β1 for treatment of muscular dystrophies.